US Family Health Plan Prior Authorization Request Form for Alpelisib (Pigray)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Step		on may be required for approval.	n (places print	١.				
1	Please complete patient and physician informat Patient Name: Address:		, , ,					
	Sponsor ID #: Date of Birth:							
Step 2	Please complete the clinical assessment:							
		the requested medication being prescribed bonsultation with an oncologist /hematologist?	?	☐ Yes ceed to question 2	□ No STOP			
		the patient GREATER THAN or EQUAL TO 18 fage?		☐ Yes	Coverage not approved □ No STOP			
	m W	as the patient been diagnosed with advanced netastatic HR positive, HER2 negative breast c vith PIK3CA mutation as confirmed by an FDA- pproved test?	ancer	☐ Yes	Coverage not approved ☐ No Proceed to question 15			
	4. Is	the patient female?	Pr	☐ Yes	☐ No Proceed to question 8			
	5. Is	the patient post-menopausal or pre-menopau	"	Post-menopausal ceed to question 9	☐ Pre-menopausal Proceed to question 6			
	6. Is	the patient receiving ovarian ablation/suppre		☐ Yes	□ No STOP Coverage not approved			
		/ill the patient use effective contraception dur nerapy and for one week after the last dose?		☐ Yes ceed to question 9	□ No STOP Coverage not approved			

US Family Health Plan Prior Authorization Request Form for **Alpelisib (Piqray)**

	8.	Will the patient use condoms and effective contraception during therapy and for one week after	☐ Yes	□ No	
		last dose?	Proceed to question 9	STOP	
				Coverage not approved	
	9.		□ Yes	□ No	
		for, adjuvant or neoadjuvant chemotherapy?	Proceed to question 10	STOP	
				Coverage not approved	
	10.	Has the patient had disease progression while on or	☐ Yes	□ No	
		after endocrine-based therapy?	Proceed to question 11	STOP	
				Coverage not approved	
	11.	Will the patient receive fulvestrant injection (Faslodex)	☐ Yes	□ No	
		therapy along with alpelisib (Piqray)?	Proceed to question 12	STOP	
				Coverage not approved	
	12.	Does the patient have a history of Stevens Johnson Syndrome, Erythema Multiforme, or Toxic Epidermal Necrolysis?	□ Yes	□ No	
			STOP	Proceed to question 13	
			Coverage not approved		
	13.	Is the provider aware and has informed patient of risk	□ Yes	□ No	
		of serious, life-threatening skin reactions, including Stevens Johnson Syndrome; severe hyperglycemia;	Proceed to question 14	STOP	
		gastrointestinal toxicity, including severe diarrhea; kidney injury; lung injury including pneumonitis;		Coverage not approved	
		pancreatitis; and severe hypersensitivity reactions?			
	14.	Is the provider aware and has informed the patient that	□ Yes	□ No	
		safety has not been established in type 1 or uncontrolled type 2 diabetic patients?	Sign and date below	STOP	
				Coverage not approved	
	15.	Please provide the diagnosis.			
			Proceed to question 16		
	16.	Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A,	☐ Yes	□ No	
		or 2B recommendation?	Sign and date below	STOP	
				Coverage not approved	
Step	100=4:	firthe above is true to the best of my knowledge	• Dloggo sign and de	uto:	
3	I certify the above is true to the best of my knowledge. Please sign and date:				
J					
		Prescriber Signature	 Date		
				[13 November 2019]	